Home » Health » Covid-19: facing BA.5, will our immunity be sufficient? Not sure, say scientists

Covid-19: facing BA.5, will our immunity be sufficient? Not sure, say scientists

This time, doubt is no longer allowed: a new epidemic wave has got off to a good start in France. The circulation of Sars-cov-2 is accelerating, the incidence has increased sharply at the national level (+53%) and the reproduction rate of the virus is again above 1, a sign that the number of cases will continue to increase . If the BA.2 variant is still dominant, the resurgence of infections is mainly driven by the rise in power of BA.5. This new member of the Omicron family accounted for just 13.3% of cases last week. A proportion already increased to 24.2% this week. “It is certain that this lineage will very soon become dominant in our country, if this is not already the case”, assures Mircea Sofonea, epidemiologist at the University of Montpellier.

What once again lead to many deaths, and disrupt our social life? Much will depend on the strength of our immunity to this newcomer. If the experts seemed quite serene at the beginning of June, the tone is changing. This new strain is indeed more transmissible than the previous ones, with greater immune escape capacities. “Different studies, including ours, show that in the absence of a booster dose, there is almost no protection against BA.5 infection. A booster induces a response against this subvariant, but the effectiveness is less marked than against Delta or BA.1, and it decreases rapidly. Four to six months after this third dose, there are very few neutralizing antibodies against BA5”, notes Prof. Olivier Schwartz, head of the Virus unit and immunity at the Institut Pasteur. In other words, individuals who received their booster several months ago remain exposed to BA.5 infection.

Half of the population already infected with Omicron or BA.2

What about vaccinated people who would have, in addition, encountered Omicron (BA.1) or its descendant BA.2? These two viral strains circulated widely in our country, in January for the first, in March and April for the second. “It is estimated that 50% of French people have been infected by one or the other, continues Professor Schwartz. This part of the population should benefit from stronger immunity against BA.5, according to several studies published in recent weeks. and carried out using the serum of vaccinated and then infected persons”. However, the level of protection seems different depending on the sub-variant. A study led by researchers at Imperial College London and released in pre-publication, without having yet been reviewed by other scientists, shows that BA.5 is genetically closer to BA.2, from which it is directly descended, than BA.1. Prior infection with BA.2 could therefore confer more effective antibodies against BA.5. “But for the moment we still have little data with subjects previously infected with BA.2, so we don’t know”, nuances Professor Jean-Daniel Lelièvre, head of the infectious diseases and clinical immunology department at the CHU. Henri-Mondor (AP-HP) in Créteil and member of the technical committee for vaccinations of the High Authority for Health.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.